Cardiogenic Shock: Causes, Symptoms, Treatment & Emergency Care Guide

 Cardiogenic shock

                                                      

Cardiogenic Shock

Cardiogenic shock refers to a condition in which there is inadequate circulation and compromised organ perfusion, primarily due to cardiac dysfunction. This failure of pump function results in an inability to maintain circulation to vital organs that, without treatment, will lead to multisystem failure and death. Cardiogenic shock is characterized by prolonged hypotension (systolic blood pressure <90 mm Hg) in the setting of decreased cardiac output (typically <1.8 L/min/m² without support and <2.2 L/min/m² with support), despite adequate intravascular volume.

Clinically, this condition is suggested when there are signs of systemic hypoperfusion manifested by cool mottled extremities, altered mentation, and/or oliguria. However, these classic signs may not always be present. Despite recent advances in management, cardiogenic shock from pump failure remains associated with a very high mortality. Among patients hospitalized with an acute myocardial infarction (AMI) complicated by cardiogenic shock, the rate of death within the first 30 days is in the range of 40–50%, although this rate has been declining with increasing use of early reperfusion therapy such as primary percutaneous coronary intervention (PCI).

Etiology

Cardiogenic shock has multiple possible causes, although the most common cause is acute myocardial dysfunction in the setting of AMI. Shock occurs in approximately 5–10% of patients with AMI. It may develop as a consequence of either left or right ventricular infarction, although hemodynamically significant right ventricular infarction occurs most commonly in combination with inferior wall left ventricular infarction.

The severity of shock from left ventricular infarction is generally related to the quantitative loss of functional myocardium, although other factors also play a role. Complications of AMI such as arrhythmias, ventricular septal defects, papillary muscle dysfunction, or myocardial rupture causing pericardial tamponade may also trigger the onset of shock.

Less frequently, cardiogenic shock may be caused by severe cardiomyopathy (dilated, hypertrophic, or stress-induced), acute myocarditis, or severe valvular disease.

 Causes of Cardiogenic Shock:

Acute Myocardial Infarction

Left ventricular pump failure

Large infarction

Smaller infarction with preexisting LV dysfunction

Mechanical Complications

Free wall rupture / tamponade

Papillary muscle dysfunction or rupture

Right ventricular infarction

Ventricular septal defect

Aortic dissection

Severe Cardiomyopathy / Congestive Heart Failure

Dilated cardiomyopathy

Stress-induced (Takotsubo) cardiomyopathy

Myocardial Injury

Acute myocarditis (infectious, toxin/drug related, transplant rejection)

Myocardial contusion

Drug-Related Causes

Calcium channel blocker overdose

Beta-blocker overdose

Acute Severe Valvular Disease

Acute mitral regurgitation (e.g., chordal rupture)

Acute aortic insufficiency

Obstruction to Left Ventricular Outflow

Hypertrophic obstructive cardiomyopathy

Aortic stenosis

Obstruction to Ventricular Filling

Pericardial effusion / tamponade

Mitral stenosis

Left atrial myxoma

Pathophysiology

Systemic inflammation triggers the release of inflammatory cytokines, which increase the activity of inducible nitric oxide synthase (iNOS). This results in increased production of nitric oxide (NO) and peroxynitrite, leading to vasodilation and a decrease in systemic vascular resistance (SVR). At the same time, myocardial infarction leads to myocardial dysfunction affecting both systolic and diastolic functions of the heart. This dysfunction causes a decrease in cardiac output and stroke volume. The reduction in cardiac output leads to decreased systemic perfusion and hypotension, which further lowers coronary perfusion pressure and contributes to myocardial ischemia. Diastolic dysfunction also increases left ventricular end-diastolic pressure (LVEDP), causing pulmonary congestion and resulting in hypoxemia, which further aggravates myocardial ischemia.

As systemic perfusion falls, the body attempts to compensate through vasoconstriction to maintain blood pressure and organ perfusion. However, the ongoing reduction in coronary perfusion and oxygen supply to the myocardium leads to progressive myocardial dysfunction. This worsening cardiac dysfunction further reduces cardiac output, creating a vicious cycle of ischemia, poor perfusion, and worsening heart failure. Eventually, this progressive deterioration of myocardial function leads to severe cardiogenic shock and ultimately death.

Patient Characteristics

Cardiogenic shock is more likely to develop in patients with AMI who are older, female, and have significant comorbidities such as diabetes, prior coronary artery disease, history of cerebrovascular disease, or renal insufficiency.

It is more common in patients with anterior myocardial infarction. Angiography often reveals the left anterior descending artery as the culprit vessel. Patients with cardiogenic shock frequently have multivessel coronary artery disease.

Signs and symptoms of cardiogenic shock usually develop after hospital admission. The majority of patients develop shock within the first 24 hours, although about 25% may develop it later, possibly due to recurrent ischemia.

Evaluation

Prompt recognition of cardiogenic shock is essential because timely and appropriate treatment can significantly reduce mortality.

Patients with low blood pressure (systolic <90 mm Hg) should be assessed quickly for:

Pulsus paradoxus (possible tamponade)

Signs of congestive heart failure

Elevated jugular venous pressure

Pulmonary edema

S3 gallop

Evidence of end-organ hypoperfusion

Cool mottled extremities

Weak pulses

Altered mental status

Reduced urine output

Investigations include:

Electrocardiogram to detect ischemia or infarction

Serum cardiac biomarkers

Bedside echocardiography to evaluate ventricular function and valve abnormalities

Pulmonary artery catheterization when diagnosis is unclear

Treatment

Initial Medical Management

Patients with cardiogenic shock require immediate stabilization to interrupt the cycle of tissue hypoperfusion and organ damage.

Typical management includes:

Central venous access

Continuous arterial pressure monitoring

Urine output monitoring

Mechanical ventilation when necessary

Patients with acute coronary syndrome should receive:

Aspirin

Consideration of antiplatelet therapy

Early revascularization when possible

Fluid resuscitation may help reverse hypotension in the absence of pulmonary congestion but must be carefully monitored.

Vasopressors

If hypotension persists, vasopressors may be required.

Commonly used agents include:

Norepinephrine (1–40 μg/min)

Dopamine (5–20 μg/kg/min)

Norepinephrine is often preferred due to fewer arrhythmias compared with dopamine.

Inotropic Agents

If blood pressure is relatively stable but cardiac output remains low:

Dobutamine (2.5–10 μg/kg/min) may improve cardiac output.

Milrinone (0.375–0.75 μg/kg/min) is another potent inotrope but may cause significant vasodilation and should be used cautiously in hypotensive patients.

Reperfusion Therapy

Early reperfusion is a key component of treatment.

Primary percutaneous coronary intervention (PCI) is the preferred method for patients with AMI complicated by cardiogenic shock. When PCI is not immediately available, thrombolytic therapy may be used as a temporary measure.

Early revascularization has been shown to significantly improve survival.

Circulatory Assist Devices

Intra-aortic Balloon Pump (IABP)

An intra-aortic balloon catheter inserted via the femoral artery provides hemodynamic support by:

Increasing coronary perfusion

Reducing afterload

Improving cardiac output

IABP may serve as a bridge to revascularization or recovery.

Ventricular Assist Devices

When medical therapy and IABP are insufficient, advanced mechanical support devices may be used.

Examples include:

Impella device

TandemHeart system

Left Ventricular Assist Devices (LVADs)

These devices improve cardiac output and organ perfusion and may serve as a bridge to recovery or transplantation.

Cardiac Tamponade

Cardiac tamponade is a cause of shock in which external compression of the heart limits ventricular filling and reduces cardiac output.

Key clinical features include:

Pulsus paradoxus

Distended jugular veins

Muffled heart sounds

Echocardiography typically confirms the presence of a significant pericardial effusion.

Treatment involves urgent pericardiocentesis or surgical drainage.

Conclusion

Cardiogenic shock is a life-threatening condition most commonly associated with acute myocardial infarction. It is characterized by severe cardiac dysfunction leading to inadequate tissue perfusion and high mortality.

Early recognition and aggressive management with medical therapy, mechanical circulatory support, and early revascularization significantly improve outcomes and survival.

Management of suspected cardiogenic shock (CS).

When CS is suspected, indicated by a systolic blood pressure (SBP) less <90 mm Hg and signs such as low cardiac output (oliguria, poor mental status, pulmonary ede ema), initial evaluation and rapid stabilization begin immediately with an electrocardiogram (ECG) to look for evidence of acute myocardial infarction (AMI), such a ST elevation, new left bundle branch block (LBBB), or suspected posterior AMI. Supplemental oxygen or mechanical ventilation is provided if there is hypoxia.

Blood pressure support is initiated with dopamine (5-15 µg/kg/min) if SBP ><90 р Hg, If SBP > 80 Mg, f SBP remains below 80 mm Hg, norepinephrine (1-2 µg/min) is used. The goal is to achieve a mean arterial pressure (MAP) of 65 mm Hg or highh All patients on vasopressors should have intra-arterial pressure monitoring.

If the ECG confirms a heart attack tevidence of AMI), but an intra-aortic balloon pur (IABP) should only be considered if the catheterization lab is not immediately availab Cardiac catheterization should be performed within 90 minutes from the onset of AMI, or within 12-18 hours from the onset of shock, granted there is no contraindica tion to anticoagulation. IABP support is also considered during this step.

If the ECG does not confirm AMI. an emergent echocardiogram is performed to es left and right ventricular (LV/RV) function and lv:1 inotropic support is provided if t patient is stable. Dobutamine (2.5-10 µg/kg/min) or milrinone (0.375-0.75 µg/kg/r are used, though milrinone should be avoided if the patient has hypotension or ren If revascularization is suitable, percutaneous coronary intervention (PCI) is recomm ended if the infarct artery is only involved, or emergent coronary artery bypass graft (CABG) is recommemded if PCI is not possible, such as in cases involving three-vessel  or PCI failure where stents and abciximab might be used, as well.

In cases of refractory shock, options such as left ventricular assist devices (LVAD) o heart transplant evaluation are considered.

Abbreviations used: CS (cardiogenic shock), SBP (systolic blood pressure), MS (mental status), ECG (electrocardiogram), AMI (acute myocardial infarction), BP (blood pressure), DBF (diastolic blood pressure), MAP (mean arterial pressure), LBBB (left bundle-branch block), D (intra-aortic balloon counterpulsation), MR (mitral regurgitation), VSD (ventricular septal de RV (right ventrick), PCI (percutaneous coronary intervention), CABG (coronary artery bypas surgery), LVAD (left ventricular assist device).